Cookie Policy

We've put some small files called essential cookies on your device to help our site work on your browser.
We also use analytical cookies to help up improve our website by collecting and reporting information on it's usage.

You can read more above this on our Privacy Policy page.

I'm ok with analytical cookies Do not use analytics cookies

Investors Video and Audio

The content of all investor relations materials contained on this website are deemed to be correct at the time of issue/publication.


Tim Watts, CEO, Shield Therapeutics presentation at the Shares Investor Event, 3 June

Jun 2020 - 24:40

Shield Therapeutics CEO says all efforts are on securing US partner for Feraccru

May 2020 - 07:15

Shield Therapeutics, Blencowe Resources and John Mayor on the Markets & Commodities

May 2020 - 42:54

Shield Therapeutics ‘very active’ on US partnering discussions with significant interest

May 2020 - 12:19

Shield Therapeutics ‘seeking to conclude US partnering discussions’

Jan 2020 - 9:18

Tim Watts, CFO, Shield Therapeutics (STX) provides an update outlining progress during 2019 which included the FDA approval of lead product, Feraccru®/Accrufer®.

Jan 2020 - 20:49

Shield Therapeutics ties up US$63million deal for Feraccru in China

Jan 2020 - 6:32

Shield Therapeutics discuss their Chinese licencing agreement plus John Meyer on Sirius and Arc Minerals

Jan 2020 - 23:30

Investival Showcase Presentations 2019 – Shield Therapeutics

Dec 2019 - 16:15

Dr Mark Sampson, CMO discusses Feraccru and data presented at UEG Week 2019

Oct 2019 - 6:18

Shield Therapeutics to present data showing Feraccru offers ‘real oral alternative’

Oct 2019 - 6:09

Tim Watts, CFO at Shield Therapeutics #STX presenting at our Life Sciences Investor Briefing

Sep 2019 - 28:21